Status:
COMPLETED
Verification Study of Ciclosporin for Atopic Dermatitis
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Severe Atopic Dermatitis
Eligibility:
All Genders
20-64 years
Phase:
PHASE3
Brief Summary
To assess the efficacy and safety of oral OL27-400MEPC 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8 weeks to patients with severe adult atopic dermatitis. THIS STUDY IS NOT ENROLLING PA...
Eligibility Criteria
Inclusion
- Appropriate the definition/diagnosis criteria of atopic dermatitis of the Japanese Dermatological Association
- Patients with severest atopic dermatitis \[according to the "Guidelines for Treatment of Atopic Dermatitis 2002, the severity of atopic dermatitis will be classified as severest when an eruption associated with severe inflammation (a lesion associated with erythema, papule, erosion, infiltration, lichenification, etc.) is noted on at least 30% of body surface on the day of subject enrollment\].
Exclusion
- \- Patients who received oral preparations, injections, inhaled preparations and suppositories of steroids or immunosuppressants other than tacrolimus hydrate ointments within 14 days of subject enrollment
- Patients who might receive the oral/injection drugs which are known to enhance nephrotoxicity, increase serum potassium levels, HMG-CoA reductase inhibitors or theophylline during the treatment period.
- Patients who received or are receiving an ultraviolet therapy (PUVA therapy, etc.)
- Patients with hypertension, active infectional disease, gout etc. Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00232076
Start Date
May 1 2004
Last Update
November 2 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.